PDF factsheet
      Z

myocardial revascularization in coronary artery disease for multivessels disease, clinical trials results

balloon angioplasty versus CABG
EAST, 1994
NCT00000465
transluminal coronary angioplasty
versus
coronary-artery bypass grafting
patients with multivessels coronary artery diseaseopen
Follow-up duration: 3 y
USA
GABI, 1994
Percutaneous transluminal coronary angioplasty
versus
coronary-artery bypass grafting
patients with symptomatic multivessel coronary diseaseopen
Follow-up duration: 1 y
Germany
BARI, 1996
NCT00000462
PTCA
versus
CABG
Patients with multivessel disease open
Follow-up duration: 5.4 y
USA, Canada
RITA, 1993
percutaneous transluminal coronary angioplasty
versus
coronary artery bypass surgery
patients with one, two, or three diseased coronary arteriesopen
Follow-up duration: 2.5 y (6.5y)
UK
ERACI, 1992
Percutaneous transluminal coronary angioplasty
versus
coronary artery bypass grafting
patients with multivessel disease and lesions suitable for either form of therapyopen
Follow-up duration: 3.8 y
Argentina
Toulouse, 1992
PTCA
versus
CABG
patients with multivessels coronary artery diseaseopen
Follow-up duration: 2.8 y
France
CABRI, 1995
percutaneous transluminal coronary angioplasty
versus
coronary artery bypass grafting
patients with symptomatic multivessel coronary diseaseopen
Follow-up duration: 1 y
Europe
PCI versus CABG
AWESOME, 2001
percutaneous coronary intervention
versus
coronary artery bypass graft
high-risk patients with medically refractory ischemia open
Follow-up duration: 5 years
US (Veterans Affairs Medical Centers)
PCI with drug-eluting stents versus CABG
FREEDOM, 2012
NCT00086450
percutaneous coronary stenting
versus
CABG
patients with diabetes and multivessel coronary artery diseaseopen
Follow-up duration: 3.8 yrs (median)
international
stent versus CABG
ARTS, 2001
Palmaz-Schatz Crown/Cross flex (Cordis)
versus
Conventional CABG
Multi vessel disease with 2 or more de novo lesion in different major arteries Total occlusion < 1monthopen
Follow-up duration: 1 year
International
CARDia (PCI), 2008
ISRCTN19872154
PCI plus stenting (and routine abciximab)
versus
CABG
Patients with diabetes and symptomatic multivessel coronary artery disease or complex single-vessel disease. open
Follow-up duration: 1 y
UK, Ireland
ERACI II, 2003
Gianturco Robin II (Cook) Primary device
versus
Conventional CABG
multi vessel disease Angina CSS III-IV; no angina but large area of heart at risk; unstable =1 vessel to be treated Lesion>3.0mmopen
Follow-up duration: 30d, 1year
Argentinad
MASS II, 2007
PCI (73% stent)
versus
CABG
patients with multivessel coronary artery disease with stable angina and preserved ventricular functionopen
Follow-up duration: 5y (1y)
South America
Myoprotect, 2004
percutaneous transluminal coronary angioplasty/stent
versus
CABG
patients with symptomatic main-stem and main-stem-equivalent lesions with substantially increased risk for bypass surgeryopen
Follow-up duration: 1 year
Europe
SOS, 2002
NCT00475449
Stent
versus
CABG
multiple vessel disease Symptomatic 1 or more vessel suitable for stentingopen
Follow-up duration: 3 years
Canada, United Kingdom, Europe
stent versus OPCAB
OCTOSTENT, 2003
NCT00975858
Stent type not reported
versus
off-pump coronary artery bypass
multi or single vessel disease Moderate LV function CABG or stenting to be considered feasibleopen
Follow-up duration: 1 year
Europe

  Options


in first

in second

  Filter